To assess the distribution of patients with stage I-II-III breast cancer to the groups “candidate to systemic NAT” or “upfront surgery”, and to determine the parameters to assign patients to systemic NAT and the type of NAT, this analysis evaluated 1276 patients at stage I-II-III with information on their clinical stage at diagnosis (Figure 1). Here, BRD2 is linked to breast cancer.